Hospital
Orleans Community Health
Orleans Community Health was paid $5.23M by Medicaid between Sep 2019 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoORLEANS COMMUNITY HEALTH
MEDINA, NY 14103
MEDINA, NY 14103
33aNPI1609873520assigned 07/07/2005
33bProvider typeCritical Access Hospital
28Total paid$5.23M
24GClaims125,537
24DCodes billed107
24AFirst – last monthSep 2019 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New York
Rank by total paid#7 of 12
Median peer was paid$5.23M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 5,212 | $114K | |
| 2020 | 16,355 | $400K | |
| 2021 | 23,429 | $657K | |
| 2022 | 30,434 | $1.86M | |
| 2023 | 28,743 | $1.37M | |
| 2024incomplete | 21,364 | $839K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 6,392 | 6,129 | $1.44M |
| 36415 | Collection of venous blood by venipuncture | 15% | 22,209 | 7,391 | $792K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 3,549 | 3,322 | $466K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.8% | 1,849 | 1,723 | $409K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.7% | 2,191 | 675 | $299K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 1,025 | 1,012 | $267K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 1,773 | 1,699 | $213K |
| 80053 | Comprehensive metabolic panel | 3.6% | 10,094 | 9,562 | $187K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.2% | 3,424 | 3,418 | $113K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 464 | 455 | $112K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,828 | 1,520 | $68K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 4,734 | 4,703 | $58K |
95 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 401 | $53K |
| 80061 | Lipid panel | 1.0% | 5,400 | $52K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 338 | $45K |
| 81025 | <1% | 606 | $43K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,904 | $42K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 250 | $42K |
| 87641 | <1% | 366 | $41K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,496 | $36K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 327 | $35K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 528 | $33K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 454 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,659 | $27K |
| 84439 | <1% | 2,525 | $27K | |
| 82607 | <1% | 1,831 | $26K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 262 | $20K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 144 | $18K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 706 | $18K |
| 87631 | <1% | 193 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,450 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,106 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 224 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 70 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 137 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,353 | $8K |
| 82746 | <1% | 578 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 119 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 37 | $8K |
| 83735 | <1% | 1,012 | $6K | |
| 82728 | <1% | 423 | $6K | |
| 84153 | <1% | 291 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 171 | $6K |
| 86703 | <1% | 326 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $5K |
| 85027 | <1% | 1,423 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 94 | $5K |
| 82570 | <1% | 847 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 356 | $5K |
| 82043 | <1% | 785 | $5K | |
| 97161 | <1% | 38 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,278 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,550 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,667 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 67 | $4K |
| 73630 | <1% | 258 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 146 | $3K |
| 85651 | <1% | 984 | $3K | |
| 81001 | <1% | 1,974 | $3K | |
| 83550 | <1% | 405 | $3K | |
| 85610 | <1% | 1,467 | $2K | |
| 86803 | <1% | 157 | $2K | |
| 72100 | <1% | 76 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,098 | $2K |
| 83540 | <1% | 302 | $2K | |
| 80305 | <1% | 263 | $2K | |
| 73610 | <1% | 100 | $2K | |
| 83690 | <1% | 1,415 | $2K | |
| 80076 | <1% | 99 | $1K | |
| 81003 | <1% | 1,178 | $1K | |
| 73030 | <1% | 75 | $1K | |
| 85730 | <1% | 993 | $931.01 | |
| 73130 | <1% | 53 | $808.15 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,683 | $685.66 |
| 87186 | <1% | 106 | $653.99 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 26 | $647.41 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 28 | $642.60 |
| 84550 | <1% | 62 | $376.74 | |
| 82150 | <1% | 209 | $363.73 | |
| 87276 | <1% | 450 | $356.11 | |
| 86780 | <1% | 24 | $352.66 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $343.38 |
| 90715 | <1% | 15 | $325.95 | |
| 84484 | <1% | 883 | $325.38 | |
| 87275 | <1% | 448 | $315.46 | |
| 84703 | <1% | 328 | $309.40 | |
| 87070 | <1% | 42 | $238.32 | |
| 0011A | <1% | 15 | $221.41 | |
| 86762 | <1% | 13 | $206.54 | |
| 83605 | <1% | 620 | $181.71 | |
| 73110 | <1% | 13 | $171.42 | |
| 87088 | <1% | 27 | $160.41 | |
| 94760 | <1% | 910 | $159.79 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 389 | $158.26 |
| 86140 | <1% | 27 | $152.97 | |
| 85378 | <1% | 51 | $152.55 | |
| 87040 | <1% | 151 | $129.78 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $93.63 |
| 85007 | <1% | 37 | $57.74 | |
| J2704 | Injection, propofol, 10 mg | <1% | 81 | $56.36 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 28 | $34.77 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,326 | $23.95 |
| 87081 | <1% | 37 | $10.44 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 989 | $6.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14 | $1.11 |
| 74022 | 0% | 27 | $0.00 | |
| 91301 | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHURTZ, MARK (C.E.O.)